口服促性腺激素释放激素拮抗剂瑞卢戈利与醋酸亮丙瑞林注射治疗子宫平滑肌瘤的比较:一项随机对照试验
这项双盲双模拟随机对照试验纳入281例子宫平滑肌瘤伴月经过多的绝经前女性,比较口服瑞卢戈利40mg每日一次与醋酸亮丙瑞林注射24周的疗效。主要终点为第6-12周 pictorial blood loss assessment chart 总分低于10分的患者比例,瑞卢戈利组82.2% vs 亮丙瑞林组83.1%,达到非劣效(差值-0.9%,95%CI -10.10至8.35,非劣效界值-15%,P=.001)。瑞卢戈利对月经出血的起效更早,停药后月经恢复更快,不良事件和骨密度下降两组相似。
要点
- 瑞卢戈利40mg口服每日一次在改善月经过多方面非劣效于亮丙瑞林注射。
- 瑞卢戈利起效更早:第2-6周PBLAC<10比例64.2% vs 31.7%。
- 停药后月经恢复中位时间瑞卢戈利37天,亮丙瑞林65天。
核心结论
- 在子宫平滑肌瘤女性中,瑞卢戈利每日一次口服治疗在改善第6-12周月经过多方面非劣效于每月亮丙瑞林注射,对月经出血起效更快,且总体耐受良好。
研究设计与样本
- 双盲、双模拟随机对照试验,纳入子宫平滑肌瘤伴月经过多(PBLAC评分至少120)的绝经前女性281例,按1:1随机分配至瑞卢戈利40mg口服每日一次(n=139)或醋酸亮丙瑞林1.88mg或3.75mg每月注射(n=142),治疗24周。
- 样本量估算每组144例(共288例),以提供至少90%把握度证明非劣效(预设非劣效界值-15%,单侧0.025显著性水平)。
主要发现
- 第6-12周PBLAC总分低于10分的患者比例瑞卢戈利组82.2% vs 亮丙瑞林组83.1%,瑞卢戈利-亮丙瑞林差值-0.9%(95%CI -10.10至8.35;预设非劣效界值-15%;P=.001)。
- 第2-6周PBLAC<10比例瑞卢戈利组64.2% vs 亮丙瑞林组31.7%(差值32.5%,95%CI 20.95-44.13%)。
- 第2-6周PBLAC=0比例瑞卢戈利组52.6% vs 亮丙瑞林组21.8%(差值30.7%,95%CI 19.45-42.00%)。
- 停药后月经恢复中位时间瑞卢戈利组37天(Q1,Q3:32.0,46.0) vs 亮丙瑞林组65天(54.0,77.0)。
- 肌瘤体积和子宫体积的缩小以及血红蛋白水平的升高两组相当;不良事件和骨密度下降两组相似。
关键数值与推荐
- 月经过多定义:PBLAC评分至少120。
- 主要终点:第6-12周PBLAC总分低于10分的患者比例。
- 非劣效界值:-15%。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To investigate the noninferiority of relugolix compared with leuprorelin acetate in reducing heavy menstrual bleeding associated with uterine leiomyomas. METHODS: In a double-blind, double-dummy trial, premenopausal women with uterine leiomyomas and heavy menstrual bleeding defined as a pictorial blood loss assessment chart score of at least 120 were randomized in a 1:1 ratio to relugolix (40 mg, oral, once daily) or leuprorelin acetate (1.88 mg or 3.75 mg, monthly injection) for 24 weeks. The primary endpoint was the proportion of patients with a total pictorial blood loss assessment chart score of less than 10 for weeks 6-12. Secondary endpoints included myoma and uterine volumes, and hemoglobin levels. A sample size of 144 patients per group (n=288) was estimated to provide at least 90% power to demonstrate noninferiority (prespecified noninferiority margin -15%; one-sided 0.025 level of significance). RESULTS: From March 2016 to September 2017, 281 patients were randomized (relugolix, n=139, leuprorelin n=142). Demographic and baseline characteristics were well balanced; mean pictorial blood loss assessment chart score was 254.3 in the relugolix group and 263.7 in the leuprorelin group. The proportion of patients with total pictorial blood loss assessment chart score of less than 10 for weeks 6-12 was 82.2% in the relugolix group and 83.1% in the leuprorelin group, demonstrating noninferiority of relugolix compared with leuprorelin (relugolix-leuprorelin difference -0.9%; 95% CI: -10.10 to 8.35; prespecified noninferiority margin -15%; P=.001). Reductions in myoma and uterine volumes and increases in hemoglobin levels were comparable in the two groups. Relugolix was associated with an earlier effect on menstrual bleeding than leuprorelin (pictorial blood loss assessment chart score of less than 10, 64.2% vs 31.7% [relugolix-leuprorelin difference 32.5%; 95% CI: 20.95-44.13%] for weeks 2-6 and pictorial blood loss assessment chart score of 0, 52.6% vs 21.8% [30.7%; 95% CI: 19.45-42.00%] for weeks 2-6) and faster recovery of menses after treatment discontinuation (relugolix median [Q1, Q3], 37 days [32.0, 46.0]; leuprorelin median, 65 days [54.0, 77.0]). Adverse events and bone mineral density loss were similar between relugolix and leuprorelin treatment groups. CONCLUSION: In women with uterine leiomyomas, once-daily treatment with relugolix, an oral gonadotropin-releasing hormone antagonist, demonstrated noninferiority to monthly leuprorelin for improvement of heavy menstrual bleeding at 6-12 weeks of treatment, had a more rapid effect on menstrual bleeding, and was generally well tolerated. CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov, NCT02655237; JAPIC Clinical Trial Information, JapicCTI-163128. FUNDING SOURCE: Takeda Pharmaceutical Company Limited and an affiliate of NovaQuest Capital Management LLC.
引用
- Osuga Y, Enya K, Kudou K, et al. Oral Gonadotropin-Releasing Hormone Antagonist Relugolix Compared With Leuprorelin Injections for Uterine Leiomyomas: A Randomized Controlled Trial. Obstet Gynecol. 2019. PMID: 30741797. doi:10.1097/AOG.0000000000003141
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。